Soar­ing De­ci­phera cap­i­tal­izes on pos­i­tive tri­al with $400M of­fer­ing; Spring­Work hires ex-For­est Labs CFO

→ Af­ter post­ing the re­sults of a suc­cess­ful late-stage study test­ing its can­cer drug, lit­tle De­ci­phera Phar­ma­ceu­ti­cals $DCPH is rais­ing gross pro­ceeds of $400 mil­lion in an of­fer­ing as it preps its mar­ket­ing ap­pli­ca­tion. Late on Wednes­day, the Waltham, Mass­a­chu­setts-based drug de­vel­op­er said it is of­fer­ing about 10.8 mil­lion shares at a price of $37/share, which is a dis­count of about 2.3% to its Wednes­day close.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER